Tripeptide Ingredients TRIZ Cases
- Compound I Crystal Forms for Stable HCV Inhibitor Formulation
Specific crystalline polymorphs of Compound I improve solubility and physical stability, enabling more reliable HCV protease inhibitor formulations.
- SN38 ADC Intermediate Linker Design for Stability Without Heavy Metals
A PEG-modified SN38 linker avoids heavy metal residues and improves ADC intermediate stability, safety, and tumor-site drug release.
- ACE-Inhibitory Tripeptide Composition for Blood Pressure Regulation
A three-amino-acid ACE-inhibitory peptide regulates blood pressure while avoiding the side effects that limit conventional hypertension drugs.
- Neurotrophin Agonist Synthesis Without Solid Support Bottlenecks
A solution-phase route replaces solid support synthesis to improve control, scalability, and industrial production of neurotrophin agonists.
- Arg-Tyr-Phe Peptide for Durable Cartilage Regeneration
An Arg-Tyr-Phe peptide stimulates glycosaminoglycan, collagen, and aggrecan production to support durable cartilage regeneration.
- Cell-Impermement Neuroproteasome Inhibitors for Tau Aggregation
Cell-impermeant inhibitors act at membrane-localized neuroproteasomes to isolate APOE-linked effects on endogenous Tau aggregation.
- Glutathione Persulfide Inhibition of Lung Ischemia-Reperfusion Injury
This case uses glutathione persulfides to limit inflammation, preserve mitochondria, and reduce pulmonary edema after transplantation.
- Granzyme B Imaging Agents for Immune Response Monitoring
Heterocyclic compounds bind Granzyme B to enable precise PET imaging, differentiating tumor growth from immune response.
- Carmaphycin B Analog Selective Immunoproteasome Inhibition
Carmaphycin B analogs selectively inhibit Plasmodium immunoproteasomes via localized beta5 subunit mutations.
- TKI-Resistant AML Treatment via Biomarker-Guided Combination Therapy
Detects CD33, CD44, and pBAD biomarkers to guide combination therapy that blocks compensatory signaling pathways and reduces viable AML blasts.
- Thieno[2,3-e]indole Alkylating Agents Tumor Targeting
Functionalized thieno[2,3-e]indole alkylating agents tethered to DNA-binding moieties via linker segments for targeted cytotoxic activity.
- Caspase-1 Inhibitors for HIV-1 Treatment
Caspase-1 inhibitors slow disease progression and reduce inflammation, addressing lifelong therapy limitations.
- Integrin Alpha v Beta 3 Antagonist Blocks Periostin Signaling
Selective integrin alpha v beta 3 antagonists inhibit periostin signaling pathways, resolving inadequate treatment effectiveness for chronic pruritus.
- Mixed Disulfide Thienopyridine Conjugates for Predictable Antiplatelet Dosing
Mixed disulfide thienopyridine conjugates release active metabolites via endogenous glutathione exchange.
- Peptide-Phospholipid Conjugates for CD36 Receptor Binding
Amide-linked peptide-phospholipid conjugates resist hydrolysis while maintaining high-affinity binding to the CD36 receptor.
- IAP Antagonist Compounds Modulating BIR3 Domain to Overcome Chemotherapy Resistance
Modified SMAC mimetics bind IAP BIR3 domains to overcome chemotherapy resistance by restoring apoptotic pathways in resistant cancer cells.
- Cationic Tripeptide Compounds Disrupt Viral Envelopes
Cationic tripeptides disrupt viral lipid envelopes, bypassing protein mutation resistance.
- Gli1 Marker for Fibrosis Detection and Myofibroblast Isolation
Gli1 isolates myofibroblasts, resolving nonspecific identification in chronic fibrosis diagnosis.
- IAP Antagonist Compounds Overcoming Chemotherapy Resistance
Specific IAP antagonists neutralize protective proteins to reverse chemotherapy resistance and induce apoptosis in cancer cells.
- Depsipeptide PI3K HDAC Inhibitor for Refractory Cancer
A depsipeptide compound combines PI3K and HDAC inhibitory activities to target cancer signaling pathways.
- Knottin Scaffold Peptides for Integrin Binding
Knottin scaffold peptides bind integrins with high affinity, overcoming low specificity of linear RGD sequences.
- Binary Conjugate for Thrombolysis and Radical Scavenging
Novel binary conjugate combines thrombolytic oligopeptide with tetrahydroisoquinoline to enhance stability and crossing efficiency.
- Acylsulfonamide Inhibitors for HCV NS3 Protease
Acylsulfonamide compounds target the HCV NS3/NS4a serine protease to modulate viral polypeptide processing and improve sustained response rates.
- Tripeptide Epoxy Ketone Proteasome Inhibitor Design
Tripeptide epoxy ketone compounds inhibit 20S proteasome activity to block tumor cell proliferation.
- Antibody-drug conjugates targeting cancer cells with hemiasterlin
Hemiasterlin derivative linked to an antibody for targeted delivery to antigen-expressing cancer cells.
- Peptide Therapeutics for Autoimmune and Bone Disease
A specific peptide sequence inhibits T cell activity and IL-6 secretion to treat bone and autoimmune diseases.
- ETA Antagonist Exosome Inhibition for Immune Checkpoint Therapy
Combining an ETA antagonist with immune checkpoint inhibitors removes exosomal PD-L1 to overcome immunosuppressive tumor microenvironments.
- Selective APP2 Inhibitor ST-115 for Cardioprotection Without Hypotension
ST-115 selectively inhibits membrane-bound aminopeptidase P2 to increase bradykinin levels.
- Tripeptoid PCNA Inhibitors for DNA Repair Pathway Specificity
Tripeptoids bind the PCNA PIP box domain, disrupting RAD6-dependent translesion synthesis and template switch pathways.
- NS3 Protease Inhibitor Peptides for Hepatitis C Treatment
Peptide compounds inhibit the NS3 protease enzyme to block viral polyprotein cleavage, addressing limited efficacy of existing interferon therapies.
- Oligopeptides P5 and P14 for Selective Melanoma Cell Cytotoxicity
Oligopeptides P5 and P14 target B-RAFV600E kinases to inhibit MAPK signaling, addressing inadequate melanoma prevention strategies.
- Stable Reduced Glutathione Composition Oxygen Depletion
Deoxygenated water and oxygen scavengers protect reduced glutathione from oxidation during storage, ensuring sustained therapeutic efficacy.
- Aminopyridine Compositions Modulating Nurr1 for Disease Treatment
Computational screening of aminopyridines identifies compounds that modulate NR4A2 activity, reducing drug development time while treating diverse conditions.
- Soybean Tripeptide Asp-Arg-Pro for ACE Inhibition
Koji-derived Asp-Arg-Pro tripeptide achieves potent ACE inhibition with minimal bitterness and side effects compared to conventional synthetic inhibitors.
- FreSH-Tracer Glutathione Monitoring for Stem Cell Quality
A fluorescent FreSH-Tracer compound detects intracellular glutathione levels in stem cells.
- D-form Peptide Targeting Annexin A1 for Brain Tumor Delivery
A D-form peptide binds annexin A1 receptors to transport anticancer agents across the blood-brain barrier.
- IAP Antagonists Modulating BIR3 Domain to Restore Apoptosis
IAP antagonists bind the BIR3 domain to disrupt caspase inhibition, restoring apoptosis pathways in chemotherapy-resistant tumors.
- Novel Peptides Enhance Collagen and Hyaluronic Acid Production
Short peptide sequences boost collagen and hyaluronic acid production while maintaining safety profiles.
- RIP3-MLKL Pathway Blocker for Skin Necroptosis Treatment
Dabrafenib targets the RIP3-MLKL pathway to treat necroptosis diseases, resolving the bottleneck of ineffective caspase-based therapies.
- Divergent Peptides for Hydroxylapatite Binding
Dendritic peptide structures overcome linear interaction limits by engaging multiple calcium sites simultaneously.
- PSMA-Targeting Multivalent Scaffold for Enhanced Binding Affinity
Segmented dendron architecture simplifies synthesis while boosting binding affinity and tumor retention.